Results 101 to 110 of about 236,269 (292)

Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis

FEBS Letters, EarlyView.
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee, Junho Jeong, Chae Yeong Lee, Hyunjoon Cho, Man Hwan Oh, Je Chul Lee, Jee‐Young Lee, Yangmee Kim   +7 more
wiley   +1 more source

Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results [PDF]

, 1994
Therapy of acute leukemia may be improved by a more accurate assessment of the effects of treatment on tumor burden and by anticipating relapse with greater precision.
Dario Campana, Campana, Dario
core   +1 more source

Assessment of minimal residual disease in childhood acute lymphoblastic leukemia

Journal of Applied Hematology, 2016
The improving cure rate of childhood acute lymphoblastic leukemia (cALL) is considered as success story in the field of oncology. It has become possible due to progressive refinement of treatment over the period of years.
Sonia K Parikh, Urmila P Uparkar
doaj   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

FEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia. [PDF]

, 2018
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Early response to therapy, especially the measurement of minimal residual disease (MRD), remains the most reliable and strongest independent prognostic parameter.
Schewe, D.M., Jeremias, I., Denis M. Schewe, Irmela Jeremias   +3 more
core   +1 more source

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Frontiers in Oncology, 2019
In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses.
Ilaria Del Giudice, Sara Raponi, Irene Della Starza, Irene Della Starza, Maria Stefania De Propris, Marzia Cavalli, Lucia Anna De Novi, Luca Vincenzo Cappelli, Caterina Ilari, Luciana Cafforio, Anna Guarini, Robin Foà   +11 more
doaj   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. [PDF]

, 2015
Minimal residual disease evaluation by multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method in treatment protocols for primary acute lymphoblastic leukemia.
BULDINI, BARBARA, Hrusak, Ondrej, Karl Seeger, Eckert C., Michael Dworzak, Karawajew L, Wolf-Dieter Ludwig, Seeger, Karl, Ratei R, Ondrej Hrusak, Günter Henze, Ludwig, Wolf-Dieter, Barbara Buldini, Rhein P, Ester Mejstrikova, Eckert, Cornelia, Cornelia Eckert, Gaipa G, Ratei, Richard, Leonid Karawajew, Arend von Stackelberg, Peter Rhein, Dworzak M, Giuseppe Gaipa, Ludwig WD, Henze G, Rhein, Peter, Hrusak O, Seeger K, BASSO, GIUSEPPE, Mejstrikova, Ester, Richard Ratei, Giuseppe Basso, Gaipa, Giuseppe, Mejstrikova E, Henze, Günter, Dworzak, Michael, von Stackelberg A, Karawajew, Leonid, Stackelberg, Arend von   +39 more
core   +1 more source

Mixed‐class J‐domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assembly

FEBS Letters, EarlyView.
Protein aggregates threaten proteostasis and cell health. In human cells, Hsp70–J‐domain protein‐based disaggregases remove aggregates, but how they assemble remains unclear. Our biochemical findings show that DNAJA2‐ and DNAJB1‐containing disaggregase scaffolds enhance luciferase aggregate targeting, and that Hsp70 recruitment by both J‐domain ...
Anna Szlachcic, Nadinath B. Nillegoda
wiley   +1 more source

Decoding the dynamic extracellular matrix in cancer—3D models and bioscaffolds rewire the rules of tumor progression

FEBS Letters, EarlyView.
Cancer progression is regulated by the dynamic matrix code of the tumor microenvironment, which influences cellular behavior and disease development. Importantly, matrix remodeling in three‐dimensional cancer models more accurately reflects in vivo conditions compared to conventional two‐dimensional systems.
Sylvia Mangani, Konstantinos Spanopoulos, Zoi Piperigkou, Nikos K. Karamanos   +3 more
wiley   +1 more source